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Most depressed patients don’t respond to their first
drug treatment, and the reasons for this treatment
resistance remain enigmatic. Human studies impli-
cate a polymorphism in the promoter of the sero-
tonin-1A (5-HT1A) receptor gene in increased sus-
ceptibility to depression and decreased treatment
response. Here we develop a new strategy to manip-
ulate 5-HT1A autoreceptors in raphe nuclei without
affecting 5-HT1A heteroreceptors, generating mice
with higher (1A-High) or lower (1A-Low) autoreceptor
levels. We show that this robustly affects raphe firing
rates, but has no effect on either basal forebrain sero-
tonin levels or conflict-anxiety measures. However,
compared to 1A-Low mice, 1A-High mice show
a blunted physiological response to acute stress,
increased behavioral despair, and no behavioral
response to antidepressant, modeling patients with
the 5-HT1A risk allele. Furthermore, reducing 5-HT1A
autoreceptor levels prior to antidepressant treat-
ment is sufficient to convert nonresponders into
responders. These results establish a causal relation-
ship between 5-HT1A autoreceptor levels, resilience
under stress, and response to antidepressants.
INTRODUCTION
Depression is one of the leading public health problems in the
world today and antidepressants are among the most commonly
prescribed medications (National Center for Health Statistics,
2007). Current evidence suggests that depressive disorders
are precipitated by stressful life events, interacting with genetic
and other predisposing factors (Caspi et al., 2003; Fava and
Kendler, 2000; Leonardo and Hen, 2006). The response to anti-
depressants, like the response to external stressors, is variable,40 Neuron 65, 40–52, January 14, 2010 ª2010 Elsevier Inc.and fewer than half of depressed patients respond to their first
drug treatment, leading to prolonged suffering and increased
medical costs (Rush et al., 2006). Elucidating the exact nature
of both the factors predisposing to depression and the mecha-
nisms underlying treatment resistance remains an important
and unmet need.
The serotonergic system modulates the acute stress response
and has been implicated in both the etiology of depression and
anxiety as well as the response to treatment (Holmes, 2008;
Lanfumey et al., 2008). Most drugs used for treating depression
increase serotonin levels, including the most commonly used
drugs, the selective serotonin reuptake inhibitors (SSRIs), which
are effective at treating both anxiety and depression (Schatzberg
and Nemeroff, 2009). Serotonin is released from serotonergic
neurons, which have cell bodies localized in the mid-brain
raphe nuclei but send axonal projections throughout the brain,
where released serotonin impacts a diverse group of serotonin
receptors.
The serotonin-1A (5-HT1A) receptor is an inhibitory G protein-
coupled receptor expressed both in serotonergic neurons (as
an autoreceptor), where it controls serotonergic tone through
feedback inhibition, and in target areas receiving serotonergic
innervation (as a heteroreceptor) (Beck et al., 1992; Hamon
et al., 1990; Riad et al., 2000). Thus, it has the dual ability to
modulate both global serotonin levels and local responses to
released serotonin. The role of 5-HT1A autoreceptors in control-
ling serotonergic tone has led to the hypothesis that these recep-
tors delay the therapeutic action of SSRIs and other drugs that
act by increasing serotonin levels (Gardier et al., 1996). Specifi-
cally, 5-HT1A autoreceptors exert negative feedback inhibition
in response to increased serotonin; thus, progressive autorecep-
tor desensitization may be responsible for the delayed onset of
action of these drugs (Blier et al., 1998).
Genetic and imaging studies in humans have suggested that
differences in 5-HT1A receptor levels or regulation are also asso-
ciated with depression, anxiety, and the response to antidepres-
sants (Le Franc¸ois et al., 2008; Lesch and Gutknecht, 2004;
Strobel et al., 2003). Most recently, an association has been
reported between a C(1019)G polymorphism in the promoter
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ables, including depression, the response to antidepressant
treatment, and amygdala reactivity (Fakra et al., 2009; Le Fran-
c¸ois et al., 2008). Although initial reports suggested that this
polymorphism might control autoreceptor levels without impact-
ing heteroreceptor levels (Lemonde et al., 2003), recent imaging
findings suggest that 5-HT1A auto- and heteroreceptors are both
affected (Parsey et al., 2006). Thus, despite significant attention
and interest regarding the role of the 5-HT1A autoreceptors in
the treatment and etiology of depression, a direct test of their
involvement has remained beyond the reach of available tech-
niques.
Studies in mice have suggested that 5-HT1A receptors are
generally involved in modulating both anxiety and depression-
related behavior (Heisler et al., 1998; Klemenhagen et al., 2006;
Parks et al., 1998; Ramboz et al., 1998), but have not usually
distinguished between auto- and heteroreceptors. 5-HT1A
knockout (KO) mice (lacking the receptor everywhere, throughout
life) display a robust anxiety-like phenotype in conflict-anxiety
paradigms, while exhibiting decreased behavioral despair in
response to stress (Heisler et al., 1998; Parks et al., 1998; Ram-
boz et al., 1998). Because behavioral despair in response to
stress is decreased by acute treatment with a number of drugs
used to treat depression, this phenotype has often been referred
to as ‘‘antidepressed.’’ However, anxiety and other stress-related
disorders such as depression are often co-morbid in humans
(Kendler et al., 1992), making the combination of an anxious
phenotype with an antidepressed phenotype in 5-HT1A KO
mice difficult to interpret. Subsequently, the antidepressed
phenotype of mice lacking the 5-HT1A receptor has been largely
ignored.
Overall, the role of 5-HT1A auto- versus heteroreceptors in
determining the response to stress, the anxiety phenotype, or
the response to treatment with antidepressants has not been
adequately addressed. Both pharmacological approaches and
genetic animal models have been hampered by the difficulty in
separating effects on autoreceptors from effects on heterore-
ceptors. To directly test the role of 5-HT1A autoreceptors in
anxiety, depression, and the response to antidepressants,
we first developed a novel system capable of suppressing
expression of 5-HT1A receptors in a tissue-specific and tempo-
rally specific manner. We used this system to examine the
biological consequences of altering autoreceptor levels without
affecting heteroreceptor levels. Specifically, we tested the
hypothesis that altering autoreceptor levels may result in differ-
ences in anxiety, stress response, depression, or response to
antidepressants.
RESULTS
Conditional Suppression of the 5-HT1A Receptor
In order to generate mice in which we could conditionally
suppress 5-HT1A receptors, we crossed mice containing two
distinct engineered alleles. The first is a knockin of the tetracy-
cline operator (tetO) into the promoter region of the murine
Htr1a gene, to create the Htr1atetO allele. The second is a trans-
gene expressing the tetracycline-dependent transcriptional
suppressor (tTS) under the control of the b-actin promoter(Figure 1A) (Mallo et al., 2003). Insertion of the tetO element
into the endogenous Htr1a locus does not interfere with normal
5-HT1A receptor expression patterns (Audero et al., 2008). tTS
suppresses endogenous expression of the 5-HT1A receptor by
binding to tetO in a doxycycline-dependent manner (Figure 1A)
(Mallo et al., 2003). Maintenance of mice on doxycycline
prevents the tTS protein from binding the tetO sequence and
results in unimpeded expression of the 5-HT1A receptor.
Since previous studies of the 5-HT1A receptor have suggested
that the receptor is involved in the developmental establishment
of anxiety-like behavior (Gross et al., 2002; Lo Iacono and Gross,
2008), a key goal of this system was achieving inducible
suppression in adulthood, in order to distinguish between devel-
opmental and adult effects of lacking the receptor. We found that
withdrawal of doxycycline allows binding of tTS to the tetO
sequence and progressive suppression of 5-HT1A receptor
levels. Four weeks after doxycycline removal, maximal suppres-
sion is achieved and 5-HT1A receptor levels are undetectable
by I125 MPPI autoradiography, revealing a half-life of receptor
disappearance of approximately 8 days (Figure S1A, available
online).
Raphe-Specific Suppression of 5-HT1A Receptors
Having established the feasibility of inducible suppression of
5-HT1A receptors in the brain, we created a mouse in which we
could specifically modulate 5-HT1A autoreceptor levels in sero-
tonergic raphe neurons without affecting heteroreceptor levels.
We accomplished this by generating a mouse with raphe-
specific expression of tTS under the control of the previously
characterized 540Z Pet-1 promoter fragment (Pet1-tTS) (Fisher
et al., 2006) (Figure 1B). We crossed these Pet1-tTs mice with
the Htr1atetO/tetO mice described above. In the presence of doxy-
cycline, mice homozygous for theHtr1atetO allele and possessing
one copy of thePet-tTS transgene display levels of 5-HT1A autor-
eceptor that are indistinguishable from littermates lacking the
tTS transgene (1A-High) (Figure S1B). Removal of doxycycline
at postnatal day 50 for 4 weeks creates a population of adult
animals with lower expression of 5-HT1A autoreceptors (1A-
Low) (Figure 1C).
Quantitative autoradiography in the raphe and selected
forebrain structures (entorhinal cortex, amygdala, and ventral
dentate gyrus) demonstrates that, compared to 1A-High mice,
1A-Low mice have indistinguishable levels of 5-HT1A heterore-
ceptor expression (Figure S1C), but display about 30% less
autoreceptor expression than 1A-High mice (Figure 1D). Similar
differences are seen in both the dorsal and median raphe (dorsal
raphe one tailed t test, t14 = 2.965, p = 0.005; median raphe one
tailed t test, t14 = 1.967, p = 0.041) (Figure 1E). An overall differ-
ence of 30% in autoreceptor levels is consistent with the range of
receptor levels that are seen within human populations (Drevets
et al., 2007).
DecreasedResponse to Agonist after Adult Suppression
of 5-HT1A Autoreceptors
To directly confirm that the differences in 5-HT1A autoreceptor
levels revealed by autoradiography had functional conse-
quences, we performed whole cell recordings in the dorsal
raphe and measured the response to the 5-HT1,7 agonistNeuron 65, 40–52, January 14, 2010 ª2010 Elsevier Inc. 41
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Figure 1. A Transgenic System for Suppres-
sion of 5-HT1A Receptors
(A) Mice homozygous for the regulatable Htr1atetO
allele, with one copy of the b-actin tTS transgene
(Htr1atetO/tetO b-act-tTS+), express 5-HT1A recep-
tors in normal patterns in the brain when main-
tained on doxycycline, assessed by 125I-labeled
MPPI autoradiography. When maintained in the
absence doxycycline, Htr1atetO/tetO b-act-tTS+
display no detectable 5-HT1A receptor expression
in the brain.
(B) Tissue-specific expression of tTS in seroto-
nergic raphe neurons was accomplished by
placing tTS under the control of a 40 kB Pet-1
mini-BAC (Pet1-tTS).
(C) Htr1atetO/tetO Pet1-tTS+ mice were maintained
on doxycycline either throughout life (1A-High) or
only until postnatal day 50 (7 weeks of age)
(1A-Low).
(D and E) 1A-High and 1A-Low mice express indis-
tinguishable levels of 5-HT1A heteroreceptors in
forebrain areas such as the hippocampus (HPC)
and entorhinal cortex (EC), while 1A-Low mice
display decreased 5-HT1A expression in the dorsal
(DR) and median (MR) raphe nuclei, assessed by
quantitative 125I-labeled MPPI autoradiography.
Values are mean luminosity ± SEM [n = 4 mice;
***p < 0.005 (DR), *p < 0.05 (MR)]. See also
Figure S1.
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5-HT1A Autoreceptors: Stress and Treatment Response5-carboxyamidotryptamine (5-CT) (Figure 2A). After recording,
we confirmed that neurons were serotonergic by filling recorded
neurons with biocytin and performing immunohistochemistry for
biocytin and TPH (Figure 2C). We observed a significantly higher
average current elicited by agonist challenge in the serotonergic
neurons of 1A-High mice versus 1A-Low mice (two tailed Mann-
Whitney test, U = 104.0; p = 0.0008) (Figure 2B). Much of this
difference resulted from a significant proportion of neurons in
the 1A-Low mice that fail to respond to the agonist challenge
(defined by current <5 pA) (c2 = 15.914; p < 0.0001) (Table S1).
These data suggest that the tTS-mediated transcriptional
suppression in the 1A-Low mice results in a mosaic population
of serotonergic neurons, some of which retain full responsive-
ness to 5-HT1A agonists while others are no longer responsive.
The reasons for this mosaicism are unclear; it may represent
all-or-nothing genetic silencing as a result of variable transgene
expression. Alternately, it may arise secondarily as a result of
further autoreceptor desensitization in some neurons with low
levels of gene expression.
To independently assess the in vivo functional status of the
5-HT1A autoreceptors in 1A-High and 1A-Low mice, we exam-
ined their hypothermic response to 5-HT1A agonist challenge.
While 1A-High mice display the expected dose-dependent
hypothermic response to the 5-HT1A agonist, 8-OH-DPAT
(repeated-measures two-way analysis of variance (ANOVA)
with time as a within-subject factor and dose as a between-
subject factor; main effect of dose F2,12 = 61.689; p < 0.0001;42 Neuron 65, 40–52, January 14, 2010 ª2010 Elsevier Inc.post hoc between vehicle and 0.1 mg/kg, p = 0.0155; between
vehicle and 0.5 mg/kg, p = 0.0001), 1A-Low mice displayed
a markedly attenuated response, which was detected only at
the higher dose (repeated-measures two-way ANOVA; main
effect of dose F2,11 = 6.109; p = 0.0164; post hoc between
vehicle and 0.5 mg/kg, p = 0.0113) (Figure 2D). These findings
are consistent with previous literature indicating that the
5-HT1A autoreceptors are responsible for the hypothermic effect
of 8-OH DPAT in the mouse (Martin et al., 1992). In summary, our
results demonstrate that a modest difference in autoreceptor
expression between 1A-High and 1A-Low mice results in robust
differences in their response to agonist treatment both in vitro
and in vivo.
Increased Spontaneous Activity of Serotonergic
Neurons Following Adult Autoreceptor Suppression
To determine whether the functional differences in autoreceptor
levels had an effect on overall serotonergic tone, we measured
the firing rates of serotonergic dorsal raphe neurons in an
in vivo anesthetized preparation. Neurons were included in the
analysis based on the characteristics of their action potentials,
and averaged traces of these action potentials are shown
as insets (Figure 3) (Vandermaelen and Aghajanian, 1983). We
observed significantly different distributions of firing rates
between the groups (two-tailed Mann Whitney test, U = 104;
p = 0.0057), with raphe neurons from 1A-Low mice more likely
to fire at higher rates (5.5 ± 0.8 Hz) than the 1A-High mice
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Figure 2. Decreased 5-HT1A Autoreceptor
Response to Agonist in 1A-Low Mice
(A) Representative current traces from whole cell record-
ings in the dorsal raphe of 1A-High and 1A-Low mice in
response to the 5-HT1A agonist 5-CT.
(B) Mean outward current amplitude in response to 100 nm
5-CT was decreased in 1A-Low mice. Values are mean ±
SEM (n = 43 1A-High and 57 1A-Low neurons; ***p < 0.001).
(C) Recorded neurons were filled with biocytin and pro-
cessed for TPH. Photomicrographs of the dorsal raphe
are shown.
(D) Hypothermic response to the 5-HT1A agonist 8-OH
DPAT. In 1A-Low mice, only the 0.5 mg/kg dose caused
a significant temperature change relative to the saline
control. In 1A-High mice, both the 0.1 mg/kg and the
0.5 mg/kg doses elicited significantly larger temperature
changes relative to control. Values are mean ± SEM
(n = 4–5/dose/group; *p < 0.05 and ***p < 0.001 for a
main effect of dose). See also Table S1.
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5-HT1A Autoreceptors: Stress and Treatment Response(2.6 ± 0.6 Hz) (two-tailed t test for group, T39 = 2.874; p = 0.0065).
This overall firing rate increase demonstrates higher seroto-
nergic tone in 1A-Low mice, consistent with decreased auto-
inhibition.
Decreasing Autoinhibition in Adult Animals Does Not
Change Baseline Anxiety Measures
Complete 5-HT1A KO mice, lacking both auto- and heterorecep-
tors throughout life, have consistently shown increased anxiety
in conflict-based tasks (Heisler et al., 1998; Klemenhagen
et al., 2006; Parks et al., 1998; Ramboz et al., 1998). To test
whether specifically modulating 5-HT1A autoreceptors in adult-
hood impacts anxiety-like behavior, we tested our mice in two
conflict-based tests: the open field paradigm and the light/dark
choice test. 1A-High and 1A-Low mice displayed no difference
in either total exploration (two-way repeated-measures ANOVA
with time as a within-subject factor and genotype as a
between-subject factor; F1,40 = 0.583; p = 0.45) or exploration
in the center of the open field (two-way repeated measuresNeuron 65ANOVA, F1,40 = 0.225; p = 0.64) (Figure 4A).
Similarly, in the light/dark test, we detected no
difference between the groups in total explora-
tion (ANOVA F1,38 = 1.105; p = 0.2998) or in the
amount of time spent in the light compartment
(ANOVA F1,38 = 0.249; p = 0.521) (Figure 4B).
These data directly demonstrate that changes
in adult levels of 5-HT1A autoreceptors do not
alter anxiety-like behavior, consistent with
previous findings suggesting a developmental
role for 5-HT1A receptors in the establishment
of anxiety-related circuitry (Gross et al., 2002;
Lo Iacono and Gross, 2008).
Decreased Autoinhibition in Adulthood
Alters Response to Stress
Studies in humans suggest that 5-HT1A receptor
levels might influence behavioral resilience to
stressful situations, with high expressors beingmore susceptible to depression than low expressors (Anttila
et al., 2007; Kraus et al., 2007; Lemonde et al., 2003; Neff
et al., 2009). Moreover, 5-HT1A KO mice display increased phys-
iological responses to acute stress (Van Bogaert et al., 2006). To
assess whether altering serotonergic autoinhibition is sufficient
to alter stress responsivity, we examined the response of
1A-High and 1A-Low mice in the stress-induced hyperthermia
paradigm (Adriaan Bouwknecht et al., 2007). This paradigm
measures one of the acute physiological responses to stress,
namely that body temperature is increased as a result of auto-
nomic system arousal. Hyperthermia in this paradigm correlates
with measures of HPA axis reactivity, such as corticosterone,
ACTH, and glucose plasma levels, and other measures of
autonomic reactivity, such as heart rate (Groenink et al., 1994).
In this test, the 1A-Low mice displayed a more robust autonomic
response to an acute stressor compared to 1A-High mice
(ANOVA F1,20 = 43.201, p < 0.0001) (Figure 4C).
Having observed a difference in a physiological response to
acute stress, we next examined the behavioral response of these, 40–52, January 14, 2010 ª2010 Elsevier Inc. 43
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Figure 3. Increased Spontaneous Neuronal Activity in the Dorsal
Raphe of 1A-Low Mice
Histograms depicting distribution of spontaneous firing rates for individual
neurons in an in vivo anesthetized preparation of 1A-High and 1A-Low animals,
with averaged action potential traces inset. The distributions are significantly
different (n = 20 and 21 neurons, respectively; two-tailed Mann Whitney test;
p = 0.0057).
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5-HT1A Autoreceptors: Stress and Treatment Responseanimals in two distinct stress-related paradigms: the tail suspen-
sion test and the forced swim test. In both tests, immobility is
scored as a measure of behavioral despair (Lucki, 1997). No
difference between groups was detected in the tail suspension
test (F1,49 = 0.001, p = 0.9735) (Figure 4D). In the forced swim
test, animals were exposed to the stressor twice over a 24 hr
period and the last 4 min of a 6 min session was scored on
each day. Unlike the tail suspension test where periods of immo-
bility appear early and occur in brief bouts throughout the dura-
tion of the test, in the forced swim test, animals are initially fairly
active with immobility generally emerging in the third minute of
the test (Buccafusco, 2009; Cryan et al., 2005; Porsolt et al.,
1977). 1A-High and 1A-Low mice responded indistinguishably
to the initial stressor on day 1 and both groups showed the
expected decrease in mobility on day 2. However, 1A-High,
but not 1A-Low mice, displayed progressively less mobility or
more behavioral despair, upon reexposure the second day
(Figure 4E) (repeated-measures ANOVA, group by time interac-B
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F3,43 = 4.535, p = 0.0047). Only 1A-High mice displayed decreased mobility ov
the final testing block. Values are mean ± SEM (n = 21, 22/group; ANOVA, betwee
44 Neuron 65, 40–52, January 14, 2010 ª2010 Elsevier Inc.tion, F3,43 = 4.535, p = 0.0047), consistent with prior results
demonstrating the need for repeated exposure to uncover
effects of serotonergic manipulations (Ramboz et al., 1998; Well-
man et al., 2007). Moreover, the mobility of the 1A-Low mice
appears to be higher than 1A-High mice during the final 2 min
of the test, suggesting a different adaptation to stress over
time in the two groups (ANOVA, between group minutes 5–6,
F1,41 = 3.953, p = 0.0535) (Figure 4E). Thus, while decreasing
adult levels of 5-HT1A autoreceptors does not alter either
conflict-based anxiety (Figures 4A and 4B) or the behavioral
response to an acute stressor (Figures 4D and 4E), decreasing
adult autoreceptor levels results in increased physiological
reactivity to stress (Figure 4C) and appears to elicit a more
active response to a repeated stress in a depression-related
task (Figure 4E).
To further test the possibility that 1A-High and 1A-Low mice
differed in their behavioral sensitivity to repeated stress, we
subjected animals to a repeated daily mild stressor, oral gavage,
for 4 weeks (28 days). This manipulation has been shown to
increase stress-response measures in rodents, such as circu-
lating corticosterone, body temperature, and heart rate (Dalm
et al., 2008). Following 4 weeks of repeated stress, 1A-High
and 1A-Low mice remained indistinguishable in their total explo-
ration in the open field (two-way repeated measures ANOVA,
F1,25 = 0.003, p = 0.9586) (Figure 5A) and in time spent in the
center of the open field (ANOVA, F1,25 = 1.587, p = 0.2195)
(data not shown) and retained their distinct physiological reac-
tivity to stress as assessed by the SIH test (one tailed t test,
t10 = 2.057, p = 0.0334) (Figure 5B). However, following repeated
mild stress, 1A-High, but not 1A-Low mice, displayed decreased
mobility over time on the first day (day 1) of the forced swim test
(paired t test for 1A-High group over time t13 = 3.492, p = 0.004
paired t test for 1A-Low group over time t13 =0.276, p = 0.7872)
(Figure 5D), a result that had only been observed after repeated
(two-day) swim stress previously (Figure 4C). Moreover,
following 4 weeks of repeated stress, 1A-High mice displayed
significantly less mobility in the tail-suspension test, compared400
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Figure 4. No Change in Anxiety-like
Behavior, but Altered Response in Stress/
Depression-Related Tests in 1A-Low Mice
(A) No group differences were detected in the total
exploration (i) or time spent in the center (ii) of the
open field. Values are mean ± SEM (n = 21/group).
(B) No group differences were detected in
percentage of time spent in the light (i) or total
path (ii) in the light/dark choice test. Values are
mean ± SEM (n = 19 and 21/group).
(C) 1A-High mice displayed an attenuated stress-
induced hyperthermic response to novel cage
stress, compared to 1A-Low mice. Values are
mean ± SEM (n = 11/group; ***p < 0.0001).
Although no differences were detected between
the groups in mobility in the tail suspension test
(D) (n = 25–26 mice/group), 1A-Low mice dis-
played increased mobility compared to 1A-High
mice across a 2 day forced swim test (E). Values
are mean ± SEM (repeated-measures ANOVA
across all time points, group by time interaction
er time on the second day of testing, and 1A-Low mice were more mobile in
n group minutes 5–6, F1,41 = 3.953, #p = 0.0535, *p < 0.05). See also Figure S2.
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Figure 5. 1A-High Mice Display a Less Active
Behavioral Response in Stressful Paradigms
Following a Repeated Mild Stressor
Following 4 weeks of a daily mild stressor, 1A-High and
1A-Low mice displayed indistinguishable behavior in the
open field paradigm (A) (n = 13–14 mice/group). 1A-Low
mice retained a more robust temperature increase in res-
ponse to novel cage stress (B) (n = 6/group; *p < 0.05),
similar to naive mice. However, after repeated stress,
1A-High mice displayed less mobility than 1A-Low mice
in the tail suspension test (C) (n = 13–14 mice/group;
*p = 0.0445) and less mobility over time in a single expo-
sure to the forced swim test (D) (n = 13–14 mice/group;
**p = 0.004). Values are mean ± SEM.
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5-HT1A Autoreceptors: Stress and Treatment Responseto 1A-Low mice (F1,25 = 4.478, p = 0.0445) (Figure 5C). This
difference emerged only after a repeated mild stressor (Fig-
ure 4D). Overall, these results are consistent with a differential
susceptibility to stress between the two groups of animals, as
measured by behavioral responses in depression-related stress
paradigms.
Decreased Autoinhibition Alters Behavioral Response
to Fluoxetine
Having demonstrated that decreased serotonergic autoinhibi-
tion yielded a consistent difference in responsiveness to stress,
we asked whether such a change might also be sufficient to
impact responsiveness to antidepressant drugs. To directly
test whether the behavioral response to antidepressant treat-
ment is affected by autoreceptor levels, we chose the novelty
suppressed feeding (NSF) paradigm (Bodnoff et al., 1988; Gross
et al., 2000; Santarelli et al., 2003). This paradigm has two
features that make it useful to model the variable human
response to antidepressants: (1) like many behavioral tests, the
response is affected by the genetic background of the mice
(Lucki et al., 2001), with some strains not responding to SSRIs
in this paradigm (Ibarguen-Vargas et al., 2008); and (2) unlike
other commonly used tests of antidepressant response, such
as the tail suspension test or the forced swim test, the NSF is
sensitive to chronic (>3 weeks) but not acute or subchronic
(<10 days) treatment with antidepressant drugs (Dulawa and
Hen, 2005; Lira et al., 2003; Wang et al., 2008). Thus, by testing
the response to fluoxetine in this paradigm we can model both
the time frame required for response to treatment and the factors
that mediate treatment response.
We administered fluoxetine or vehicle to 1A-High and 1A-Low
mice and tested them in the NSF paradigm, a test of hyponeo-
phagia that measures the latency of a mouse to consume foodNeuron 65placed in the middle of a brightly lit, aversive
arena (Bodnoff et al., 1988; Gross et al., 2000;
Santarelli et al., 2003). Following a chronic,
26 day treatment with fluoxetine, we observed
that 1A-Low mice respond robustly, as shown
by their lower latency to feed relative to their
vehicle-treated controls (p = 0.0031 by Mantel-
Cox log rank test) (Figure 6D). However, no
response to fluoxetine was observed in the
1A-High mice (p = 0.8475 by Mantel-Cox logrank test) (Figure 6C). Thus, like many mouse strains, the 1A-
High mice do not respond to fluoxetine in this paradigm. Further-
more, this experiment establishes a causal relationship between
5-HT1A autoreceptor levels and response to antidepressants;
namely, a decrease in 5-HT1A autoreceptor levels in adulthood,
prior to antidepressant treatment, is sufficient to confer respon-
siveness to fluoxetine in an otherwise treatment-resistant
population.
To determine whether autoreceptors might determine time to
response, we also examined the response of both 1A-High and
1A-Low mice to subchronic (8 day) treatment with fluoxetine.
Under these conditions, 1A-Low mice show a robust response
to fluoxetine (p = 0.011 by Mantel-Cox log rank test), while no
such response is seen in the 1A-High mice (p = 0.2343 by
Mantel-Cox log rank test) (Figures 6A and 6B). This result
suggests that decreased autoreceptor function may permit an
early response to treatment, consistent with the hypothesis
that feedback inhibition by 5-HT1A autoreceptors delays the
onset of response by limiting the initial increase in serotonin
(Artigas et al., 1996).
Serotonin Levels in 1A-High and 1A-Low Mice
Are Indistinguishable at Baseline, but Differ
Significantly in Response to Fluoxetine Challenge
Having observed behavioral differences between 1A-High and
1A-Low mice in response to challenge with both repeated stress
and serotonin transporter blockade, we next asked how these
differences were reflected at the neurochemical level. We per-
formed in vivo microdialysis in two representative forebrain
areas: the ventral hippocampus (vHPC) and the prefrontal cortex
(PFC). Despite the differences in basal raphe firing, no difference
was detected in serotonin levels at baseline between the groups
in either the vHPC or PFC (two-way ANOVA for brain region and, 40–52, January 14, 2010 ª2010 Elsevier Inc. 45
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Figure 6. Robust Response to Fluoxetine Treat-
ment in the NSF Test in 1A-Low, but Not 1A-High,
Mice
(A and B) 1A-High mice treated for 8 days with fluoxetine
(18mg/kg/day p.o.) display no difference in latency to
consume a food pellet in the middle of an aversive arena
as compared to 1A-High mice treated with vehicle, while
1A-Low mice treated with fluoxetine for 8 days display
a shorter latency than their vehicle controls.
(C and D) Continuation of fluoxetine treatment for 26 days
failed to decrease the latency to feed in 1A-High mice,
while 1A-Low mice still displayed a shorter latency to
feed than their vehicle controls. Inset bar graphs depict
mean latencies ± SEM (n = 11–13/treatment/group;
*p < 0.05, **p < 0.01 by Mantel-Cox log-rank test). See
also Figure S3.
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5-HT1A Autoreceptors: Stress and Treatment Responsegroup, main effect of group, F1,26 = 0.006, p = 0.937) (Table 1).
Following 8 days of fluoxetine treatment, we observed a differ-
ence in serotonin levels in the vHPC, with higher levels of sero-
tonin in the 1A-Low animals (two-way ANOVA for brain region
and group, main effect of group, F1,22 = 9.705; p = 0.005; region
by group interaction, F1,22 = 8.977; p = 0.0067; post hoc for group
in the vHPC, p = 0.003). Interestingly, serotonin levels continued
to increase in both groups with chronic fluoxetine treatment.
Differences in extracellular serotonin levels were normalized
between the groups by 26 days of fluoxetine treatment, in both
forebrain areas measured (two-way ANOVA for brain region
and group, main effect of group, F1,24 = 0.202, p = 0.657).
To further dissect the neurochemical effects of fluoxetine on
mice with different levels of serotonergic autoinhibition, we
assessed changes in serotonin levels in response to an acute
challenge with fluoxetine or saline. Both groups of mice dis-
played significant increases in serotonin in response to acute
fluoxetine treatment compared to saline in both the vHPC
(Figures 7A and 7B) (two-way ANOVA, main effect of group,
F1, 26 = 4.352, p = 0.0469; main effect of treatment, F1, 26 = 37.822,
p < 0.0001; group by treatment interaction, F1, 26 = 4.512,
p = 0.0433; post hoc for treatment in 1A-High mice, p < 0.0001;
post hoc for treatment in 1A-Low mice, p = 0.0042) and theTable 1. Serotonin Levels Measured by In Vivo Microdialysis in 1A-High and 1A-Low
Naive 8 Days Fluoxetine
HPC PFC HPC PF
1A-High 2.6 ± 0.2 2.2 ± 0.4 3.1 ± 0.3 2.
1A-Low 2.7 ± 0.4 2.1 ± 0.4 6.8 ± 0.9** 2.
Mean basal serotonin levels (fmol/20 ml dialysate) ± SEM in ventral hippocampus (HPC) and pr
in HPC.
46 Neuron 65, 40–52, January 14, 2010 ª2010 Elsevier Inc.PFC (Figures 7C and 7D) (two-way ANOVA,
main effect of group, F1, 26 = 6.769, p = 0.0151;
main effect of treatment, F1, 26 = 23.080, p <
0.0001; post hoc for treatment in 1A-High
mice, p < 0.0065; post hoc for treatment in 1A-
Low mice, p = 0.0039). However, 1A-Low mice
displayed a larger increase in 5-HT in response
to fluoxetine in both brain regions (post hoc
for group in fluoxetine-treated animals in thevHPC, p = 0.0474; post hoc for group in fluoxetine-treated
animals in the PFC, p = 0.0251), consistent with increased sero-
tonergic tone in these animals.
5-HT1A Autoreceptors Desensitize after Chronic
Treatment with Fluoxetine
One long-standing hypothesis states that 5-HT1A autoreceptor
desensitization both delays response and is necessary for behav-
ioral response to occur (Blier et al., 1998). Thus, to ensure that
the lack of behavioral response to fluoxetine in 1A-High mice
was not due to a failure of autoreceptor desensitization, we
assessed the animals’ hypothermic response to 8-OH DPAT
after chronic fluoxetine treatment. While 1A-High mice treated
chronically with vehicle displayed a robust hypothermic
response to 8-OH DPAT challenge (repeated-measures two-
way ANOVA, main effect of dose F1,6 = 35.477, p = 0.001; dose
by time interaction F1,5 = 5.080, p = 0.0017), 1A-High mice treated
chronically with fluoxetine no longer responded to 8-OH-DPAT
challenge (repeated-measures ANOVA, main effect of dose
F1,6 = 0.085, p = 0.781; dose by time interaction F1,5 = 1.479,
p = 0.226) (Figure 8A). This result is in agreement with previous
reports showing desensitization of 5-HT1A autoreceptors fol-
lowing chronic treatment with a number of drugs used to treatMice Treated with Fluoxetine
26 Days Fluoxetine
C HPC PFC
4 ± 0.5 10.8 ± 1.2 3.2 ± 0.4
5 ± 0.4 10.5 ± 0.8 3.3 ± 0.3
efrontal cortex (PFC). **p < 0.01 compared to 1A-High
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Figure 7. Increased Serotonin Levels in Response
to Fluoxetine in 1A-Low Mice
Extracellular serotonin levels measured by in vivo micro-
dialysis in the vHPC (A) and PFC (C) of naive 1A-High
and 1A-Low mice, following acute challenge with fluoxe-
tine (18 mg/kg, i.p.) or saline. Values are mean ± SEM for
each time point. Total extracellular 5-HT, measured by
area-under-the-curve analysis, increases in the vHPC (B)
and PFC (D) of both 1A-High and 1A-Low mice in response
to acute fluoxetine treatment. 1A-Low mice display a larger
increase in extracellular 5-HT than 1A-High mice in both
brain areas. Values are mean ± SEM (n = 6–9 mice/group;
*p < 0.05, **p < 0.01, ***p < 0.001).
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5-HT1A Autoreceptors: Stress and Treatment Responsedepression, including SSRIs (Blier et al., 1998). A similarly atten-
uated response to 8-OH-DPAT challenge is seen in 1A-Low mice
treated chronically with both vehicle (two-way repeated-
measures ANOVA, main effect of dose F1,6 = 1.252, p = 0.306;
dose by time interaction F1,5 = 2.831, p = 0.0328) and fluoxetine
(repeated-measures ANOVA, main effect of dose F1,6 = 0.922,
p = 0.374; dose by time interaction F1,5 = 3.537, p = 0.0124)
(Figure 8B), consistent with the blunted response we observed
previously in these animals (Figure 2D). Therefore these results
suggest that desensitization of 5-HT1A autoreceptors alone isTe
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Neuron 65not sufficient for the behavioral response to
fluoxetine, but rather that 5-HT1A -mediated
serotonergic tone prior to treatment is critical
for establishing treatment response.
DISCUSSION
tetO-Based Gene Suppression
Conditional KO and transgenic mice are
powerful tools for probing the behavioral rolesof genes expressed in the brain. In practice, however, most
approaches have been limited by ectopic expression, lack of
temporal control, or irreversibility.
These weaknesses are largely overcome in the system pre-
sented here. We use an adaptation of the tetO-inducible strategy
that relies on insertion of tetO sites into the endogenous
promoter of a gene of interest. In the case of the Htr1atetO/tetO
mice used here, this insertion is largely silent (i.e., does not
noticeably alter the pattern of 5-HT1A receptor expression) in
the absence of tTS. We have now successfully generated silentFigure 8. Loss of 5-HT1A Agonist Response in
1A-High Mice Treated with Chronic Fluoxetine
(A) 1A-High mice treated with vehicle for 35 days display
a robust hypothermic response to 0.5 mg/kg 8-OH
DPAT challenge, while those treated with fluoxetine for
35 days do not, demonstrating full desensitization of
5-HT1A autoreceptors in 1A-High mice after fluoxetine
treatment. Values are mean ± SEM for each time point
(n = 3/group/treatment/dose; **p < 0.01, main effect of
dose; p = 0.002, dose by time interaction; *p < 0.05,
**p < 0.01, ***p < 0.001 for between dose comparisons
at each time point).
(B) 1A-Low mice treated with vehicle display a similarly
attenuated response to those treated with fluoxetine,
consistent with decreased 5-HT1A autoreceptor levels
and function (n = 3/group/treatment/dose; p < 0.05,
dose by time interaction) in these mice. Values are
mean ± SEM for each time point.
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5-HT 5-HTT5-HT1AR
1A-High
No Response to Fluoxetine
Behavioral Despair
Models human G/G carriers
1A-Low
Behavioral Despair
Response to Fluoxetine
Models human C/C carriers
Serotonergic tone
Serotonergic tone
Figure 9. Model of 5-HT1A Autoreceptor Effects on the Serotonergic
Raphe
Diagram depicts representative raphe neurons in 1A-High and 1A-Low
animals, emphasizing the differences between the two groups. 1A-High
mice have lower basal firing rate (indicated above the cell) and high levels of
somatodendritic 5-HT1A autoreceptor, which exert robust inhibitory effects
on raphe firing. This results in increased behavioral despair in response to
stress, compared to 1A-Low mice. Conversely, 1A-Low mice have a higher
basal firing rate and low levels of somatodendritic 5-HT1A autoreceptors,
which exert less inhibitory control over raphe firing rates. This results in less
behavioral despair in response to stress, compared to 1A-High mice. While
1A-High mice do not respond behaviorally to treatment with the antidepres-
sant fluoxetine, 1A-Low mice display a robust behavioral response. 1A-High
and 1A-Low mice provide a mechanistic model for humans carrying, respec-
tively, the G/G and C/C alleles of the Htr1aI C(1019)G polymorphism.
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5-HT1A Autoreceptors: Stress and Treatment ResponsetetO insertions in several other genes (data not shown), suggest-
ing that this strategy is broadly generalizable.
Expression of the 5-HT1A receptor in this system is tightly
suppressed by a ubiquitously expressed tTS binding to tetO
sequences that are knocked in to the endogenous Htr1a
locus. Importantly, suppression can be achieved at any point
in the life of the animal by withdrawing doxycycline. Further-
more, specificity of gene suppression is dictated by an over-
lap between transgenic tTS expression patterns and endoge-
nous expression of the gene. This ensures that tTS-mediated
suppression only occurs in cells that normally express the
gene of interest, eliminating the possibility for ectopic gene
expression. Finally, another advantage of this system is that,
unlike systems that rely on genetic recombination, suppression
can be reversed in the presence of doxycycline (data not
shown).
Modeling the Human Htr1a C(1019)G Polymorphism
Our 1A-High and 1A-Low mice provide a mechanistic model of
one of the predicted consequences of the recently identified
human Htr1a C(1019)G polymorphism: namely, that it results
in differential transcriptional suppression of the Htr1a gene in
serotonergic neurons and creates populations of individuals
with higher and lower expression of 5-HT1A autoreceptors. Initial
in vitro characterization of expression driven off this polymorphic
allele revealed preferential suppression of the C-allele by several
transcription factors in a raphe-derived cell line, but not in cell
lines derived from other brain areas. This suggested that C
carriers might express lower levels of 5-HT1A autoreceptor
than G-carriers (Lemonde et al., 2003). However, the only sub-
sequent binding study to report an association between the
G-allele and increased 5-HT1A receptor binding reported
increases in both the raphe and other brain regions (Parsey
et al., 2006). It remains unclear whether the human polymor-
phism directly affects 5-HT1A gene expression throughout the
brain or whether the changes in forebrain levels are a secondary
consequence of a primary change in autoreceptors.
Consequences of Decreased 5-HT1A Autoreceptor
Levels in Adulthood
Our data from 1A-High and 1A-Low mice provides the first direct
evidence for a functional model incorporating the predictions
generated from both preclinical and clinical studies, including
the recent human Htr1a C(1019)G polymorphism studies
(Albert and Lemonde, 2004; Lesch and Gutknecht, 2004). In
this model, 5-HT1A autoreceptor-modulated intrinsic raphe firing
rates are directly related to resilience under stress and to the
response to antidepressant treatment, demonstrated here with
the prototypical SSRI fluoxetine (Figure 9). In such a model,
when the serotonergic system is activated, higher intrinsic 5-
HT1A autoreceptor levels (either in 1A-High mice or G/G individ-
uals) results in lower raphe firing rate and lower intrinsic 5-HT1A
autoreceptor (in 1A-Low mice or C/C individuals) results in higher
raphe firing rate. The increased raphe firing rate (in 1A-Low mice
or C/C individuals) would increase resilience to chronic stress by
increasing serotonin release throughout the brain upon chal-
lenge, as seen by the decreased behavioral despair of 1A-Low
mice following stress. Interestingly, our data suggests that at48 Neuron 65, 40–52, January 14, 2010 ª2010 Elsevier Inc.baseline (i.e., non-stressful conditions), levels of serotonin do
not differ between the 1A-High and 1A-Low mice.
Studies in rats treated chronically with SSRIs have shown an
initial decrease of raphe firing at the beginning of treatment, with
firing rates recovering to baseline following chronic treatment
and 5-HT1A autoreceptor desensitization (Blier et al., 1998). Thus,
in the presence of an SSRI, we expect 5-HT1A autoreceptor-medi-
ated inhibition of raphe firing to occur in both 1A-High and 1A-Low
animals,albeit todifferentextents. Indeed, 1A-Lowanimalsdisplay
faster increases in extracellular serotonin in the hippocampus
upon repeated (8 day) fluoxetine treatment, directly reflecting
differential autoinhibition in response to reuptake blockade. Inter-
estingly, extracellular serotonin levels reach a similar plateau in
both 1A-High and 1A-Low animals following chronic (26 day)
treatment and autoreceptor desensitization, demonstrating that
the behavioral differences between the groups cannot be fully
explainedbyextracellular serotonin levels. Because our behavioral
groups differ only by the levels of their 5-HT1A autoreceptors at
the start of treatment, the differences in behavioral response to
fluoxetine must be mediated by either differential downstream
changes or subtler differences in serotonergic tone.
In summary, two of the main associations from studies of the
C(1019)G polymorphism in humans are recapitulated in our
model: susceptibility to stress and response to antidepressant
treatment. In addition, our data suggest that the effects of the
polymorphism may be easier to detect under conditions of
chronic stress or pharmacological intervention.
Behavioral Dissociation and Treatment Implications
Together with previous work, this study also establishes a double
dissociation of 5-HT1A receptor function in baseline anxiety- and
Neuron
5-HT1A Autoreceptors: Stress and Treatment Responsedepression-related behavior between development and adult-
hood. Previous work has shown that transgenic developmental
overexpression of 5-HT1A in the forebrain is sufficient to establish
normal anxiety-like behavior, regardless of 5-HT1A receptor
status at the time of testing (Gross et al., 2002). Furthermore,
pharmacological blockade of 5-HT1A receptors in development
but not adulthood is sufficient to increase anxiety-like behavior
in WT mice (Lo Iacono and Gross, 2008). The data presented
here demonstrate the complementary point: specific manipula-
tion of 5-HT1A autoreceptors in adulthood is sufficient to impact
reactivity to stress- and depression-related behavior without
affecting conflict-anxiety measures.
Finally, this study underscores the difference between
decreased intrinsic 5-HT1A-mediated autoinhibition and desen-
sitization of 5-HT1A autoreceptors. Specifically, one canonical
hypothesis postulates that 5-HT1A autoreceptor desensitization
determines the behavioral response to antidepressant treat-
ment. Our data does not support this hypothesis, as 1A-High
mice displayed desensitized autoreceptors (in terms of both 8-
OH DPAT hypothermia and extracellular serotonin levels), yet
do not respond behaviorally to fluoxetine treatment. Conversely,
mice that differed only by possessing lower autoreceptor levels
before treatment—1A-Low mice—displayed a robust behavioral
response to fluoxetine after both chronic (26 day) and sub-
chronic (8 day) treatment.
Indeed, we conclude that 5-HT1A autoreceptor desensitization
alone is not sufficient for the response to fluoxetine to occur, as
1A-High mice display a desensitized 8-OH DPAT response but
do not respond behaviorally to chronic fluoxetine treatment.
Rather, our data suggest that serotonergic tone—governed by
intrinsic autoreceptor levels—prior to the onset of treatment is
critical for establishing responsiveness and time to response.
Thus, we predict that treatments aimed at increasing seroto-
nergic tone prior to beginning SSRI administration might prove
to be more efficacious and even faster acting than current
antidepressant therapies, particularly for individuals with higher
autoreceptor levels, such as those carrying the G/G alleles of
the C(1019)G polymorphism.
EXPERIMENTAL PROCEDURES
Transgenic Mice
Htr1atetO mice were generated by removing a loxP-flanked pGK-neo transcrip-
tional stop cassette from Htr1aSTOP-teto KO mice by crossing to an HSP70-cre
line that deletes in the germline (Dietrich et al., 2000; Gross et al., 2002). The
resulting Htr1atetO mice contain a tetO-CMV promoter inserted 50 of the
Htr1a coding region and express the 5-HT1A receptor in a pattern that is indis-
tinguishable from the wild-type. b-actin tTS+ Htr1atetO/tetO mice were created
by breeding mice with tTS expressed under the control of a human b-actin
transgene (Mallo et al., 2003) onto a background homozygous for the Htr1atetO
allele. Tg(Pet-1-tTS) was produced by cloning the coding sequence of tTS
protein followed by an SV40 polyadenylation signal (Deuschle et al., 1995)
into the T3 polylinker region of the NarI/BgzA modification 5 plasmid, placing
the coding sequence downstream of a b-globin promoter (Scott et al., 2005).
The b-globin promoter and tTS coding sequence were then released with an
RsrII digest and the resulting fragment was cloned into the EPet-1 Mini-BAC
Mod#1 containing a 40 kb genomic DNA fragment (540z) that lies upstream
of the Pet-1 coding sequence (Scott et al., 2005). The resulting BAC EPet-1-tTs
was linearized and subjected to pronuclear injection into B6CBA/F2 hybrid
zygotes. Founders were identified by PCR using the primers (50-TTGATCAC
CAAGGTGCAGAG-30 and 50-CAGGGCTCTTCTCCCTTCTC-30). Pet-1-tTS+Htr1atetO/tetO mice were generated for behavioral experiments by breeding
the Pet-1-tTS mice onto Htr1atetO/tetO background. Pet-1-tTS+ Htr1atetO/tetO
males were then bred to Htr1atetO/tetO females. As a result, the Pet-1-tTS trans-
gene was transmitted through the male germline, ensuring that all pups were
raised by mothers of the same genotype, regardless of doxycycline status.
All experiments were conducted on male offspring. Animals were maintained
on a mixed 129S6/Sv; C57B6; CBA background.
Pet-1-tTS+ Htr1atetO/tetO mice and their Pet-1-tTS Htr1atetO/tetO littermates
were fed chow containing 40 mg/kg doxycycline (Bioserv) throughout devel-
opment to prevent tTS-mediated transcriptional suppression of the 5-HT1A
receptor. This chow was otherwise identical in composition to standard labo-
ratory chow (described below). At 50 days postnatal, animals were randomly
split into two groups; one continued receiving doxycycline chow (1A-High)
and the other began receiving doxycycline-free standard laboratory chow
(1A-Low) (Prolab Isopro RMH 3000; PMI Nutrition International). To control
for the possible effects of doxycycline on behavior, littermate controls lacking
the tTS transgene, in which doxycycline had no effect on 5-HT1A receptor
expression, were also tested in baseline behavioral experiments (Figure S2).
Animal Husbandry
Animals were housed in groups of between three and five per cage and had
access to food and water, ad libitum. Animals were maintained on a 12:12
light/dark schedule, and all testing was conducted during the light period.
Animal protocols were approved by the Institutional Animal Care and Use
Committee and were conducted in accordance to the National Institutes of
Health Guide for the Care and Use of Laboratory Animals.
Receptor Autoradiography
Mice of the ages indicated were sacrificed by cervical dislocation and decap-
itation. Extracted brains were frozen immediately on crushed dry ice (75C)
and maintained at 80C until sectioning. Brains were cryosectioned at a
thickness of 18 mm and sections were thaw-mounted on Superfrost slides
(Fisher). Sections were maintained at 80C until processing.
125I-MPPI—4-(20-Methoxyphenyl)-1-[20-(n-200-pyridinyl)-p-
[125I]iodobenzamido]ethylpiperazine) Binding
Mounted sections were processed for 125I-MPPI autoradiography using
a previously described method (Kung et al., 1995; Ramboz et al., 1998).
Sections were exposed to BioMax MR film (Kodak) for a period of between
6 and 72, hours, depending on the activity of the ligand at time of binding.
All experimental and control brains within a group were processed and
exposed to film as a batch. Films were digitized at a resolution of 1200 dpi
using an Epson 3200 Photo Scanner, and signal density was measured using
the mean luminosity function in Adobe Photoshop, as described previously
(Rattiner et al., 2004; Ressler et al., 2002). Levels of 5-HT1A binding were
determined by analyzing the region of interest and subtracting from a same-
size adjacent ‘‘background’’ region of tissue lacking specific binding, to obtain
a normalized luminosity value for each region of interest. Signals were deter-
mined to be within the linear range of the film by comparison to a standard
curve constructed from an ARC146-F 14C standard (ARC).
Electrophysiology
Whole-Cell Recordings
Whole cell recordings of dorsal raphe neurons were made as previously
described (Beck et al., 2004). Briefly, 200 mm coronal slices were taken
throughout the rostrocaudal extent of the dorsal raphe and maintained in
oxygenated ACSF for a 1 hr recovery period. Dorsal raphe neurons were visu-
alized and the membrane was patched and then ruptured as described (Beck
et al., 2004). Following collection of passive membrane characteristics, cells
were voltage clamped at 60 mV and the current response to application of
100 nM 5-CT was recorded. If cells showed no response to 5-CT, the
GABAB antagonist baclofen (30 mM) was added and the cell response was
measured. Cells that did not respond to 5-CT or baclofen were excluded
from the analysis. After recording, cells were biocytin filled and identified as
serotonergic by colabeling with TPH.
In Vivo Recordings
Single-unit potentials were collected with an Axoclamp 2A amplifier, Digitdata
1440A/D converter (Molecular Devices), and were amplified (1003) and filteredNeuron 65, 40–52, January 14, 2010 ª2010 Elsevier Inc. 49
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and collected on-line using Clampex 10.1 software (Molecular Devices).
A serotonin neuron was characterized by a biphasic action potential that
was approximately 2 ms in duration. A stable baseline of spontaneous activity
was recorded for at least 3 min. Multiple neurons per mouse were recorded
through multiple descents. Only firing rates within two standard deviations of
the mean were included in the analysis.
Intracerebral In Vivo Microdialysis
Mice were treated with fluoxetine for 0, 8, or 26 days, as indicated (18 mg/kg,
p.o.). Extracellular 5-HT levels were measured by in vivo microdialysis as previ-
ously described (Guiard et al., 2008). Briefly, after the last dose of fluoxetine,
two concentric dialysis probes were implanted in the vHPC and PFC (outer
diameter3 active length: 0.33 1.6 and 0.3 mm3 2 mm, respectively) of anes-
thetized mice (chloral hydrate, 400 mg/kg, i.p.). Stereotaxic coordinates
(in mm) were as follows: PCF: A = 1.6, L = 1.3, V = 1.6; vHPC: A = 2.8,
L = 3.0, V = 3.0 (Franklin and Paxinos, 1997). Animals were allowed to recover
for a period of 24 hr. Following recovery, probes were continuously perfused
with a CSF, and dialysate was collected every 15 min for analysis by HPLC
amperometry (Guiard et al., 2008). Baseline 5-HT levels were calculated as
the average of the first four samples, ± SEM. Freely moving mice were treated
(t = 0) with either a challenge dose of fluoxetine (18 mg/kg; i.p.) or its vehicle,
and dialysate samples were collected for a 0–120 min post-treatment period.
The limit of sensitivity for 5-HT was 0.5 fmol/sample (signal-to-noise ratio 2).
Following sample collection, brains were removed and sectioned to ensure
proper probe placement.
Behavioral and Physiological Testing
All animals used for behavioral testing were age matched within 2 weeks.
Animals were initially tested at 11–13 weeks of age, at least four weeks after
the cessation of doxycycline in 1A-Low animals. Baseline anxiety tests were
completed before other behavioral tests. Fluoxetine was given after baseline
behavioral and physiological measures were assessed, at 18 mg/kg/day p.o.
for up to 28 days. Testing in the NSF paradigm occurred on day 26 of treatment.
8-OH DPAT-Induced Hypothermia
Body temperature was assessed intrarectally, using a lubricated probe
inserted approximately 2 cm and a Thermalert TH-5 thermal monitor (Physi-
temp). Mice were singly housed in clean cages for 10 min, and three baseline
body temperature measurements were taken. Ten minutes after the third base-
line measurement, animals received 8-OH DPAT i.p. at the doses indicated and
body temperature was monitored every 10 min for a total of 60 min. Tempera-
tures are represented as a change from the final baseline measurement.
Stress-Induced Hyperthermia
Stress-induced hyperthermia paradigm measures a physiologic response to
a stressful stimuli (Adriaan Bouwknecht et al., 2007). Briefly, animals in their
home cages were moved to a testing room and allowed to acclimate for
1 hr. One animal per cage was removed and a baseline body temperature
was measured intrarectally. Each animal was then placed in a novel, clean
cage for 10 min, after which a second body temperature was recorded.
Open Field Test
Exploration in response to a novel open field was measured as described
(Weisstaub et al., 2006), with the following modifications: (1) animals were
singly housed for at least 30 min prior to testing to minimize order effects within
a cage, (2) light levels in the open field chambers were maintained at 10–20 lux
to encourage exploration of the full environment, (3) animals were placed in
a corner of the maze and allowed to explore the center at will, and (4) the
test was conducted for a total of 30 min. Dependent measures were total
path length (cm), number of entries into the center, time in the center, and
percent age of distance in the center (distance traveled in the center divided
by the total distance traveled).
Light/Dark Choice Test
Exploration of the light/dark chamber was measured as described (Klemenha-
gen et al., 2006). Dependent measures were total distance and percentage of
time spent in the light compartment.
Modified Forced Swim Test
Behavioral response to forced swimming was assayed as described previ-
ously (David et al., 2007). Briefly, mice were placed into clear plastic buckets50 Neuron 65, 40–52, January 14, 2010 ª2010 Elsevier Inc.20 cm in diameter and 23 cm deep filled 2/3 of the way with 26C water and
videotaped from the side for 6 min. Only the last 4 min were scored. All animals
were exposed to the swim test on two consecutive days. Scoring was done
using an automated Viewpoint Videotrack software package. Dependent
variables were immobility, swimming, and climbing.
Tail Suspension Test
Mice were suspended by the tail using tape to secure them to a horizontal bar.
The animals were suspended for 5 min and immobility during this period was
assessed using an automated Viewpoint Videotrack software package.
Repeated Mild Stressor
Animals were gavaged daily with 10 ml/kg/day of drinking water for 28 days
prior to testing.
Novelty Suppressed Feeding
Testing was performed as previously described (David et al., 2007). Briefly,
animals were food restricted for 24 hr and were place in a 403 60 cm brightly
lit arena (800–900 lux) with a food pellet placed in the center. Latency of the
animals to begin chewing food was recorded. Immediately after the latency
was recorded, the food pellet was removed from the arena. The animals
were then placed in their home cage and the amount of food consumed in
5 min was measured (home cage consumption), followed by an assessment
of post-restriction weight. Percentage of body weight lost and home cage
consumption were assessed as relative measures of animal hunger. No effect
of fluoxetine was observed in home cage measures (Figure S3).
Statistical Analysis
In general, the effect of treatment or dose was analyzed using an ANOVA,
using repeated measures where appropriate. Significant ANOVAs were
followed up with Fisher PLSD test for behavioral and physiological measures
and with Student-Neuman-Keuls t test for electrophysiological characteriza-
tion. In the case of the NSF paradigm, survival analysis was performed and
statistical differences were determined using the Kaplan-Meier product-limit
method.SUPPLEMENTAL INFORMATION
Supplemental Information includes one table and three figures and can be
found with this article online at doi:10.1016/j.neuron.2009.12.003.
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